ReviewJournal of medical virology2021
Impact of disease-modifying drugs on the severity of COVID-19 infection in multiple sclerosis patients.
Review in Journal of medical virology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 27 citations in OpenAlex.
- Causality between COVID-19 and multiple myeloma: a two-sample Mendelian randomization study and Bayesian co-localization.Clinical and experimental medicine · 2024Article
- Knowledge mapping of COVID-19 and autoimmune diseases: a visual and bibliometric analysis.Clinical and experimental medicine · 2023Article
- Safety, immunogenicity, efficacy, and acceptability of COVID-19 vaccination in people with multiple sclerosis: a narrative review.Neural regeneration research · 2023Review
- A comprehensive review of COVID-19 symptoms and treatments in the setting of autoimmune diseases.Virology journal · 2023Review
- Article
- No genetic causal association between systemic lupus erythematosus and COVID-19.Frontiers in immunology · 2023Article
- COVID-19 and inflammatory bowel disease crosstalk: From emerging association to clinical proposal.Journal of medical virology · 2022Review
- [The corona pandemic and multiple sclerosis: vaccinations and their implications for patients-Part 1: recommendations].Der Nervenarzt · 2021Review
- Symptoms after COVID-19 Infection in Individuals with Multiple Sclerosis in Poland.Journal of clinical medicine · 2021Article
- Impact of the COVID-19 pandemic on access to healthcare services amongst patients with multiple sclerosis in the Lazio region, Italy.European journal of neurology · 2021Article
- COVID-19 severity and outcome in multiple sclerosis: Results of a national, registry-based, matched cohort study.Multiple sclerosis and related disorders · 2021Article
- Vaccination and multiple sclerosis in the era of the COVID-19 pandemic.Journal of neurology, neurosurgery, and psychiatry · 2021Review
- Emerging COVID-19 Neurological Manifestations: Present Outlook and Potential Neurological Challenges in COVID-19 Pandemic.Molecular neurobiology · 2021Review
- Prevalence of coronavirus disease 2019 in patients with neuromyelitis optica in Isfahan, Iran, and a review on recent reports and literature.Current journal of neurology · 2021Article
- Prolonged SARS-CoV-2 Illness in a Patient Receiving Ocrelizumab for Multiple Sclerosis.Open forum infectious diseases · 2021Article
- Multiple sclerosis and COVID-19: How could therapeutic scenarios change during the pandemic?Journal of medical virology · 2021Article
- Impact of disease-modifying drugs on the severity of COVID-19 infection in multiple sclerosis patients.Journal of medical virology · 2021Review
- Update on cerebrovascular manifestations of COVID-19.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2020Review
Corrections and comments
- Commented on by
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent evidence suggested that neurological manifestations occur in patients with a severe form of coronavirus disease (COVID-19). On the basis of this issue, neurologists are very concerned about patients with neurological disorders, especially multiple sclerosis (MS), as consumers of immunosuppressive or immune-modulating drugs. Therefore, the administration of proper disease-modifying therapies (DMTs) in MS patients is critical during the pandemic status. On the one hand, both the autoimmune diseases and immunosuppressive drugs increase the risk of infection due to impairment in the immune system, and on the other hand, postponing of MS treatment has serious consequences on the central nervous system. In the present study, we discussed recent literature about the effect of DMTs administration on the severity of COVID-19 in the MS patients. Overall, it seems that DMTs do not provoke the COVID-19 infection in the MS patients by declining immune responses and cytokine storm. However, as a precaution, the supervision of a neurologist is highly recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.